Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety observation of Ormutivimab Injection for rabies exposure
ChiCTR2400094152Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ormutivimab in rabies, sponsored by Peking University First Hospital. Primary endpoint: Body temperature. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
ormutivimab
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR2400094152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094152.